Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ |
| |
| Authors: | Nils D. Arvold MD Rinaa S. Punglia MD MPH Melissa E. Hughes MSc Wei Jiang MS Stephen B. Edge MD Sara H. Javid MD Christine Laronga MD Joyce C. Niland PhD Richard L. Theriault DO MBA Jane C. Weeks MD MSc Yu‐Ning Wong MD MSCE Sandra J. Lee ScD Michael J. Hassett MD MPH |
| |
| Affiliation: | 1. Harvard Radiation Oncology Program, Harvard Medical School, Boston, MassachusettsFax: (617) 732‐7347;2. Department of Radiation Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts;3. Department of Medical Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts;4. Department of Surgery, Brigham & Women's Hospital, Boston, Massachusetts;5. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York;6. Department of Surgery, University at Buffalo, Buffalo, New York;7. Department of Surgery, University of Washington Medical Center, University of Washington School of Medicine, Seattle, Washington;8. Comprehensive Breast Program, Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;9. Department of Information Sciences, City of Hope National Medical Center, Duarte, California;10. Department of Breast Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas;11. Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts;12. Department of Biostatistics and Computational Biology, Dana‐Farber Cancer Institute, Boston, Massachusetts Presented at the 47th Annual Meeting of the American Society of Clinical Oncology;13. June 4‐8, 2011;14. Chicago, IL. The views expressed in this article are those of the authors, and no official endorsement by the Agency for Healthcare Research and Quality or the US. Department of Health and Human Services is intended or should be inferred |
| |
| Abstract: | BACKGROUND: The number of women diagnosed with ductal carcinoma in situ (DCIS) is increasing. Although many eventually develop a second breast cancer (SBC), little is known about the characteristics of SBCs. The authors described the characteristics of SBC and examined associations between the pathologic features of SBC and index DCIS cases. METHODS: Women were identified in the National Comprehensive Cancer Network Outcomes Database who were diagnosed with DCIS from 1997 to 2008 and underwent lumpectomy and who subsequently developed SBC (including DCIS or invasive disease that occurred in the ipsilateral or contralateral breast). The Fisher exact test and the Spearman test were used to examine associations between the pathologic characteristics of SBC and index DCIS cases. RESULTS: Among 2636 women who underwent lumpectomy for DCIS, 150 (5.7%) experienced an SBC after a median of 55.5 months of follow‐up. Of these 150 women, 105 (70%) received adjuvant radiotherapy, and 50 (33.3%) received tamoxifen for their index DCIS. SBCs were ipsilateral in 54.7% of women and invasive in 50.7% of women. Among the index DCIS cases, 60.6% were estrogen receptor (ER)‐positive, and 54% were high grade, whereas 77.5% of SBCs were ER‐positive, and 48.2% were high grade. Tumor grade (P = .003) and ER status (P = .02) were associated significantly between index DCIS and SBC, whereas tumor size was not (P = .87). CONCLUSIONS: After breast conservation for DCIS, SBC in either breast exhibited pathologic characteristics similar to the index DCIS, suggesting that women with DCIS may be at risk for developing subsequent breast cancers of a similar phenotype. Cancer 2012. © 2012 American Cancer Society. |
| |
| Keywords: | ductal carcinoma in situ breast‐conserving therapy lumpectomy radiation tamoxifen second breast cancer contralateral breast cancer grade estrogen receptor |
|
|
